

Giovanni Rossi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1644674/publications.pdf>

Version: 2024-02-01

26
papers

760
citations

567144

15
h-index

580701

25
g-index

26
all docs

26
docs citations

26
times ranked

1279
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients. <i>Journal of Translational Medicine</i> , 2019, 17, 74.	1.8	103
2	Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges. <i>Cancers</i> , 2020, 12, 17.	1.7	82
3	Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients. <i>Oncologist</i> , 2018, 23, 936-942.	1.9	69
4	Radiomic Detection of EGFR Mutations in NSCLC. <i>Cancer Research</i> , 2021, 81, 724-731.	0.4	57
5	Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 125.	2.2	53
6	Concomitant medications during immune checkpoint blockage in cancer patients: Novel insights in this emerging clinical scenario. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 142, 26-34.	2.0	49
7	Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab. <i>Journal of Clinical Medicine</i> , 2019, 8, 1011.	1.0	45
8	Comparison Between ¹⁸ F-FDG PET-CT-Based and CT-Based Criteria in Non-Small Cell Lung Cancer Patients Treated with Nivolumab. <i>Journal of Nuclear Medicine</i> , 2020, 61, 990-998.	2.8	44
9	Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient. <i>Cancers</i> , 2020, 12, 1125.	1.7	43
10	Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab. <i>Journal of Clinical Medicine</i> , 2019, 8, 1566.	1.0	26
11	Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1351-1358.	2.0	24
12	Metabolic Parameters as Biomarkers of Response to Immunotherapy and Prognosis in Non-Small Cell Lung Cancer (NSCLC): A Real World Experience. <i>Cancers</i> , 2021, 13, 1634.	1.7	23
13	Exploring Response to Immunotherapy in Non-Small Cell Lung Cancer Using Delta-Radiomics. <i>Cancers</i> , 2022, 14, 350.	1.7	22
14	Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 573-585.	1.0	21
15	Acquired resistance in oncogene-addicted non-small-cell lung cancer. <i>Future Oncology</i> , 2018, 14, 29-40.	1.1	18
16	The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab. <i>Cancers</i> , 2021, 13, 3117.	1.7	17
17	Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer. <i>Clinical and Experimental Metastasis</i> , 2019, 36, 449-456.	1.7	15
18	Current state of the art and future perspectives with immunotherapy in the management of small cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1427-1435.	1.0	13

#	ARTICLE	IF	CITATIONS
19	Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus. <i>Immunotherapy</i> , 2019, 11, 873-879.	1.0	12
20	New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 19-33.	0.9	6
21	Serum levels of VCAM-1 are associated with survival in patients treated with nivolumab for NSCLC. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13668.	1.7	5
22	A Circulating Risk Score, Based on Combined Expression of Exo-miR-130a-3p and Fibrinopeptide A, as Predictive Biomarker of Relapse in Resectable Non-Small Cell Lung Cancer Patients. <i>Cancers</i> , 2022, 14, 3412.	1.7	4
23	Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment. <i>Clinical and Translational Oncology</i> , 2020, 22, 1603-1610.	1.2	3
24	Safety and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: focus on challenging populations. <i>Immunotherapy</i> , 2021, 13, 509-525.	1.0	3
25	Prognostic value of immunotherapy-induced organ inflammation assessed on 18F-FDG PET in patients with metastatic non-small cell lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3878-3891.	3.3	3
26	Cancer pathways analysis and correlation with survival in patients with advanced stage non-small cell lung cancer treated with PD-1 inhibitor. <i>Journal of Clinical Oncology</i> , 2021, 39, e21007-e21007.	0.8	0